pdufa.bio
Home › Decisions › PGEN 2026-05-27

PGEN FDA decision — May 27, 2026

✓ APPROVED

Precigen Inc. — PAPZIMEOS (zopapogene imadenovec-drba) · Recurrent Respiratory Papillomatosis (RRP).

Run-up into the decision (T-120 → T+5)

PDUFA 5/27/26$5.21$3.112/10/25
Daily close, T-120 (12/10/25) through T+5. Run-up high $5.21 on 2/19/26, low $3.1 on 3/27/26 (T-120 to T-1). FDA decision 5/27/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-05-27
OutcomeApproved
Drug / candidatePAPZIMEOS (zopapogene imadenovec-drba)
CompanyPrecigen Inc.
120-day run-up (T-120→T-1)+21.8%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio